Chat with us, powered by LiveChat Cancer Diagnostics Market by Type, By Age group and Region, Global Forecast 2023 to 2032

Cervical Cancer Diagnostics Market

 
Enquiry Before Buying
Request Sample
 

Cervical Cancer Diagnostic Market By Type (Pap Smear Tests, HPV test, Biopsy and ECC, Colposcopy Tests, Others), By Age group (20 to 40 years, above 40 years): Global Opportunity Analysis and Industry Forecast, 2023-2032

Sep 2023
Total Pages: 100

At a compound annual growth rate of 5.1%, the size of the worldwide Cervical Cancer Diagnostics market is projected to reach $12.9 billion by 2032.

The Global Cervical Cancer Diagnostic Market ($ billion)

 

 

 

 

 

 

 

 

Cervical cancer is a disease in which malignant cancer cells form in the cervix. The major cause of cervical cancer is long-lasting infection control with some forms of human papillomavirus (HPV). All women are at risk of developing cervical cancer treatment. However, it occurs most often in women aged 30. The spike in the number of cervical cancer cases has led to increase the demand for cervical cancer diagnostics across the globe.

Cervical Cancer Diagnostic Market Scope :

Metrics Details
Base Year 2023
Historic Data 2018-2022
Forecast Period 2024-2032
Study Period 2018-2032
Forecast Unit Value (USD)
Revenue forecast in 2032 $ 12.9 billion
Growth Rate CAGR of 5.1 % during 2022-2032
Segment Covered By Type, By Age group, Regions
Regions Covered North America, Europe, Asia Pacific, South America, Middle East and Africa
Key Players Profiled F. Hoffmann-La Roche Ltd., Abbott Molecular, Quest Diagnostics, Inc., Becton, Dickinson and Company, QIAGEN, OncoHealth Corporation, Hologic Inc., CooperSurgical, Inc., Arbor Vita Corporation 

Furthermore, rapidly rising female elderly population are more likely to develop this serious illness. Thus, there is rapid demand for early detection of the disease which is expected to fuel the growth of the market in the future. However, changes in regulatory policies for cervical cancer screening will hinder the growth of the market in the next few years.

The aim of the report is to estimate the market size for cervical cancer diagnostics and the future growth potential of the market for cervical cancer diagnostics across various segments, such as test type, and end-users.

The market has been studied for historic years from 2018 and 2019, with the base year of estimation as 2019 and forecast from 2020 to 2028. Factors such as growing prevalence of cervical cancer worldwide, increase in awareness programs for cervical cancer screening along with rise in female geriatric population susceptible to the disease are the key drivers of the cervical cancer diagnostics market.

By test type, Pap smear test held substantial share of the global cervical cancer diagnostics market. The Pap test is the most commonly used test to detect cancer and changes that may lead to cancer.

North America dominated the global cervical cancer diagnostics market in 2019. The dominant share is attributable to high prevalence of HPV infections in the U.S. For instance, approximately 11,000 females suffer from HPV infections every year in the U.S. Moreover, number of awareness programs for cervical cancer screening, favorable reimbursement scenario is expected to fuel growth of the market in the region.

Asia Pacific is projected to witness lucrative growth over the coming years owing to high incidence cervical cancer in the developing countries such as India and China. According to Globocan 2020, there were 123,907 new cases of cervical cancer in India and 109,741 new cases in China. This is likely to augment the growth of the market in the region.

Key Segments of the Global Cervical Cancer Diagnostics Market

By Type Overview, 2023-2032 (USD billion)

  • Pap Smear Tests
  • HPV test
  • Biopsy and ECC
  • Colposcopy Tests
  • Others

By Age group Overview, 2023-2032 (USD billion)

  • 20 to 40 years
  • above 40 years

Regional Overview, 2023-2032 (USD billion)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Important Companies in Global Cervical Cancer Diagnostics Market

  • F. Hoffmann-La Roche Ltd.
  • Abbott Molecular
  • Quest Diagnostics, Inc.
  • Becton, Dickinson and Company
  • QIAGEN
  • OncoHealth Corporation
  • Hologic Inc.
  • CooperSurgical, Inc.
  • Arbor Vita Corporation


Frequently Asked Questions (FAQ) :
The major contenders in the global market are cervical cancer diagnostics market include F. Hoffmann-La Roche Ltd., Abbott Molecular, Quest Diagnostics, Inc., Becton, Dickinson and Company, QIAGEN, OncoHealth Corporation, Hologic Inc., CooperSurgical, Inc., Arbor Vita Corporation
The Global cervical cancer diagnosticsMarket is Segmented on the basis of type ,By Age group, Regions
The base year for the report is 2023 in cervical cancer diagnostics market



1.   Introduction
               1.1. Introduction 
               1.2. Market Definition and Scope
               1.3. Units, Currency, Conversions and Years Considered
               1.4. Key Stakeholders
               1.5. Key Questions Answered
2.   Research Methodology
               2.1. Introduction
               2.2. Data Capture Sources
               2.3. Market Size Estimation
               2.4. Market Forecast
               2.5. Data Triangulation
               2.6. Assumptions and Limitations
3.   Market Outlook
               3.1. Introduction
               3.2. Market Dynamics
                              3.2.1.    Drivers
                              3.2.2.    Restraints
                              3.2.3.    Opportunities
                              3.2.4.    Challenges
               3.3. Porter’s Five Forces Analysis
               3.4. Regulatory Landscape
               3.5. COVID-19 Impact Analysis
4.   Cervical Cancer Diagnostics Market By Type, 2023-2032 (USD billion) 
               4.1. Pap Smear Test
               4.2. HPV Test
               4.3. Cervical Biopsies
               4.4. Cystoscopy
5.   Cervical Cancer Diagnostics Market By Age group, 2023-2032 (USD billion) 
               5.1. 20 to 40 years
               5.2. above 40 years
6.   Cervical Cancer Diagnostics Market by Region, 2023-2032 (USD billion)
               6.1. North America
                              6.1.1.    US
                              6.1.2.    Canada
               6.2. Europe
                              6.2.1.    UK
                              6.2.2.    Germany
                              6.2.3.    France
                              6.2.4.    Spain 
                              6.2.5.    Italy
                              6.2.6.    Rest of Europe
               6.3. Asia Pacific
                              6.3.1.    China
                              6.3.2.    Japan
                              6.3.3.    India
                              6.3.4.    Rest of APAC
               6.4. Latin America
                              6.4.1.    Brazil
                              6.4.2.    Mexico
                              6.4.3.    Rest of Latin America
               6.5. Middle East & Africa
                              6.5.1.    GCC
                              6.5.2.    South Africa
                              6.5.3.    Rest of Middle East & Africa
7.   Competitive Landscape
               7.1. Company Ranking/Market Share Analysis
               7.2. Strategic Initiatives
                              7.2.1.    Mergers & Acquisitions
                              7.2.2.    New Product Launch
                              7.2.3.    Investments
                              7.2.4.    Expansion
                              7.2.5.    Others
8.   Company Profiles
               8.1. F. Hoffmann La Roche Ltd.
               8.2. Abbott Molecular
               8.3. Quest Diagnostics, Inc.
               8.4. Becton, Dickinson and Company
               8.5. QIAGEN
               8.6. OncoHealth Corporation
               8.7. Hologic Inc.
               8.8. CooperSurgical, Inc.
               8.9. Arbor Vita Corporation
               8.10.Other Prominent Players